EGFR and non-small cell lung carcinoma: Erlotinib (ERL) is a very lipophilic drug (clog P ~ 3.2) and potent epidermal growth factor receptor (EGFR) inhibitor (IC50 ~ 2 nM) currently marketed as tablets (Tarceva®) for the treatment of EGFR mutation-positive non-small-cell lung cancer [1,2].